Brief: Alzamend Neuro Submits IND Application For A Phase IIA Clinical Trial
13/11/2023 14:29
Nov 13 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO SUBMITS IND APPLICATION FOR A PHASE IIA
CLINICAL
TRIAL IN POST-TRAUMATIC STRESS DISORDER PATIENTS OF
NEXT-GENERATION LITHIUM THERAPEUTIC DRUG CANDIDATE AL001
Source text for Eikon: ID:nBw6fWVx2a
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview